Adocia Valuation
Is ADOC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ADOC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ADOC (€8.14) is trading below our estimate of fair value (€12.02)
Significantly Below Fair Value: ADOC is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ADOC?
Key metric: As ADOC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ADOC's PS Ratio? | |
|---|---|
| PS Ratio | 34.5x |
| Sales | €3.59m |
| Market Cap | €124.02m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 35.3x |
| Enterprise Value/EBITDA | -8.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ADOC's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.8x | ||
IPH Innate Pharma | 3.7x | 26.2% | €123.7m |
TNG Transgene | 15.9x | 2.9% | €103.2m |
ALCLS Cellectis | 5x | 29.2% | €171.2m |
GNFT Genfit | 2.5x | 20.1% | €200.4m |
ADOC Adocia | 34.5x | 70.2% | €124.0m |
Price-To-Sales vs Peers: ADOC is expensive based on its Price-To-Sales Ratio (34.5x) compared to the peer average (6.8x).
Price to Sales Ratio vs Industry
How does ADOC's PS Ratio compare vs other companies in the FR Biotechs Industry?
Price-To-Sales vs Industry: ADOC is expensive based on its Price-To-Sales Ratio (34.5x) compared to the French Biotechs industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is ADOC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 34.5x |
| Fair PS Ratio | 0.9x |
Price-To-Sales vs Fair Ratio: ADOC is expensive based on its Price-To-Sales Ratio (34.5x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Euroapi
€325.6m
Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use.
EAPI
€3.42
7D
-2.9%
1Y
-37.5%
Sanofi
€113.9b
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
SAN
€90.87
7D
-3.7%
1Y
5.4%
Theranexus Société Anonyme
€3.9m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€0.51
7D
0.4%
1Y
-57.1%